An Analysis of Agios Pharmaceuticals Inc. (AGIO)’s Potential Price Growth


In a filing, Agios Pharmaceuticals Inc. revealed its Principal Accounting Officer Washburn Theodore James Jr. unloaded Company’s shares for reported $12242.0 on Mar 03. In the deal valued at $24.29 per share,504 shares were sold. As a result of this transaction, Washburn Theodore James Jr. now holds 2,741 shares worth roughly $ 62001.420000000006.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Then, Schenkein David P sold 20,000 shares, generating $507,400 in total proceeds. Upon selling the shares at $25.37, the Director now owns 117,879 shares.

Before that, Washburn Theodore James Jr. sold 233 shares. Agios Pharmaceuticals Inc. shares valued at $6,340 were divested by the Principal Accounting Officer at a price of $27.21 per share. As a result of the transaction, Washburn Theodore James Jr. now holds 2,668 shares, worth roughly $60350.16.

Piper Sandler initiated its Agios Pharmaceuticals Inc. [AGIO] rating to an Overweight in a research note published on Monday, February 03, 2023; the price target was $41. PT values the company’s stock at a premium of 44.83 to its Monday closing price. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in mid November from “a Sell” to “a Neutral”. SVB Leerink also remained covering AGIO and has increased its forecast on July 27, 2022 with a “an Outperform” recommendation from previously “Mkt perform” rating. BofA Securities started covering the stock on December 03, 2021. It rated AGIO as “a Buy”.

Price Performance Review of AGIO

On Monday, Agios Pharmaceuticals Inc. [NASDAQ:AGIO] saw its stock jump 2.96% to $22.62. On the same session, the stock had its day’s lowest price of $21.66, but rose to a high of $23.005. Over the last five days, the stock has lost -6.41%. Agios Pharmaceuticals Inc. shares have fallen nearly -19.44% since the year began. Nevertheless, the stocks have fallen -28.01% over the past one year. While a 52-week high of $34.76 was reached on 01/26/23, a 52-week low of $16.75 was recorded on 03/10/23. SMA at 50 days reached $27.68, while 200 days put it at $26.56. A total of 0.76 million shares were traded, compared to the trading of 0.58 million shares in the previous session.

Levels Of Support And Resistance For AGIO Stock

The 24-hour chart illustrates a support level at 21.85, which if violated will result in even more drops to 21.08. On the upside, there is a resistance level at 23.20. A further resistance level may holdings at 23.77. The Relative Strength Index (RSI) on the 14-day chart is 28.21, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.92, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.33%. Stochastics %K at 14.42% indicates the stock is a buying.

How much short interest is there in Agios Pharmaceuticals Inc.?

A steep rise in short interest was recorded in Agios Pharmaceuticals Inc. stocks on Jan 30, 2023, dropping by -1.0 million shares to a total of 5.77 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 6.77 million shares. There was a decline of -17.33%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 11.85% of the overall stock float, the days-to-cover ratio (short ratio) fell to 11.35.

Agios Pharmaceuticals Inc. [AGIO] – Who Are The Largest Shareholders?

In filings from Wellington Management Co. LLP, it is revealed that the company now owns 5,462,657 shares, or roughly 9.94% of the outstanding AGIO shares. In other words, the investor’s shares have risen by 314,244 from its previous 13-F filing of 5148413.0. Additionally, The Vanguard Group, Inc. increased 2.10% of its stake after which the total value it holdings stand at $132,691,370, while Bellevue Asset Management AG reduced -0.05% of its stake to hold $102.68 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 14,847 shares of Agios Pharmaceuticals Inc., while SSgA Funds Management, Inc. bought 544,296 shares. At present, Rock Springs Capital Management L is holding 2,996,592 shares valued at $75.84 million. Armistice Capital LLC owned 2,750,000 shares of the company at the time of its most recent 13F filing, worth $69.6 million.

According to FactSet, Agios Pharmaceuticals Inc.’s share price will average $36.83 in the next year, based on opinions of analysts polled by the firm. This is up nearly 72.96 percent from its previous closing price of $21.97. Analysts expect Agios Pharmaceuticals Inc. stock to reach the higher price of $41.00, while the lowest price estimate is $32.00. However, 9 analysts have rated AGIO stock as an Overweight in their predictions for 2023.


Please enter your comment!
Please enter your name here